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With-No-Lysine [K] (WNKs) are a recently discovered family
of serine/threonine protein kinases that contain a uniquely
structured catalytic domain. Mutations in the genes
encoding two family members, WNK1 and WNK4, cause a
chloride-dependent, thiazide-sensitive inherited syndrome
of hypertension and hyperkalemia. Over the past
5 years, physiologic studies have demonstrated that
these proteins regulate transcellular and paracellular
epithelial ion flux. In this mini review, we discuss WNK1
and WNK4 gene products and their regulatory effects
on sodium chloride and potassium handling in the
aldosterone-sensitive distal nephron. Experimental
observations regarding the effects of these proteins on
transport processes mediated by the thiazide-sensitive
Na–Cl co-transporter, the epithelial sodium channel, the renal
outer medullary potassium channel, and the paracellular
pathway integrate into a model that suggests an essential
role for WNKs in coordinating renal Na–Cl reabsorption
and Kþ secretion.
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The With-No-Lysine [K] (WNK) kinases are a family of
proteins that play critical roles in the regulation of epithelial
ion transport. Interest in this group of serine/threonine
kinases increased with the discovery that mutations in WNK1
and WNK4 are linked to familial hyperkalemic hypertension
(FHHt, also known as pseudohypoaldosteronism type II, or
Gordon syndrome), a human disease characterized by
excessive renal sodium chloride and potassium retention.1
Emerging evidence implicates WNKs in regulating apical,
basolateral, and paracellular ion transport pathways across
diverse epithelia, and has been the subject of several excellent
reviews.2–5 In this mini review, we narrow our focus to the
role of WNK signaling in sodium chloride and potassium
transport processes of the aldosterone-sensitive distal ne-
phron (ASDN), which by current definitions includes the late
distal convoluted tubule (DCT2), connecting tubule, and
cortical collecting duct. In particular, we emphasize an
inhibitory WNK cascade that regulates electroneutral sodium
reabsorption via the thiazide-sensitive Na–Cl co-transporter
(NCC). The discovery of this cascade has revealed a novel
network of proteins coordinating sodium chloride and
potassium homeostasis in the distal nephron, and uncovered
downstream effectors of aldosterone that permit it to serve its
dual function as a mediator of renal sodium reabsorption and
kaliuresis.
FHHt IS CAUSED BY MUTATIONS IN WNK1 AND WNK4
The connection between WNK kinases and the regulation of
kidney ion transport was made through positional cloning
studies of patients with FHHt. This autosomal-dominant
disorder is defined by the unusual triad of hypertension,
hyperkalemia, and normal glomerular filtration rate.3 Less
universal features of the syndrome include hypercalciuria
and distal renal tubular acidosis, suggesting that at least a
subset of patients carry a phenotype that is essentially the
‘mirror image’ of Gitelman’s syndrome.5 Studies in human
subjects established that the elevated blood pressure and
potassium levels seen in FHHt are treatable with thiazide
diuretics or infusion of sodium with poorly reabsorbable
anions, such as sulfate or bicarbonate.3,5 These results
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indicate that FHHt is a distal nephron disorder of excessive
chloride reabsorption.
Positional cloning approaches to determine the cause of
the disease proved difficult initially, because the disease
appeared to be genetically heterogeneous,3 but in 2001,
Wilson et al.1 made the seminal discovery that WNK1 and
WNK4 gene mutations are linked to two subtypes of FHHt.
In the two studied kindreds with WNK1 mutations, affected
patients inherited large deletions within the first intron; these
deletions were associated with a fivefold upregulation of
wild-type WNK1 transcript in leukocytes. In contrast,
families with WNK4 mutations carried missense mutations
within the coding sequence of the gene. These mutations
were localized within short stretches of amino acids that were
highly conserved among WNK family members.
The WNK kinases had been discovered just 1 year before
Wilson’s study. Xu et al.6 identified this family of proteins in
their search for novel members of the mitogen-activated
protein/extracellular signal-related protein kinase family, a
group of kinases remarkable for their substrate selectivity. To
date, most of the biochemical work in the field (reviewed by
Xu et al.4) has focused on WNK1 and WNK4, the two FHHt-
associated paralogs. WNK1 was immediately recognized as
structurally distinct from other serine/threonine kinases
owing to the atypical placement of an essential catalytic
lysine residue outside of its usual position in beta strand 3 of
the kinase domain.4 Instead, this lysine is present in beta
strand 2. The kinase domains are near the amino terminus;
just downstream from the kinase domain is an autoinhibitory
domain that suppresses intrinsic kinase activity and possesses
cross-inhibitory effects toward other WNK family mem-
bers.7,8 Nearer to the carboxyl terminus are two predicted
coiled-coil domains that are believed to play an important
role in binding partner interactions.
Despite the unusual arrangement of residues within their
kinase domains, WNKs are catalytically active. WNK1 and
WNK4 phosphorylate themselves and each other, and these
events appear to contribute to their kinase activities.7 They
have also been shown to possess catalytic activity against a
number of proteins, including the tonicity-responsive kinases
SPAK/PASK and OSR1,9,10 members of the claudin family,2
and the membrane-trafficking regulator synaptotagmin-2.4
Importantly, the kinase activity of WNK1 is activated by both
hyper- and hypotonicity, and has been demonstrated to be
sensitive to osmotic stressors such as Na–Cl, K–Cl, and
carbohydrates such as mannitol and glucose.6,7 The catalytic
activities of WNKs likely yield downstream effects that are
pleiotropic; for instance, within the 5 years that have elapsed
since its discovery, WNK1 has been implicated in a variety of
non-epithelial processes, including insulin signaling, cellular
growth, and organogenesis.3,4
TISSUE EXPRESSION OF WNK1 AND WNK4 GENE PRODUCTS
WNK4
Wilson et al.1 reported that WNK4 is expressed predomi-
nantly by the kidney, where it is present along the ASDN. The
distribution of WNK4 in the ASDN is not however, uniform;
it appears to localize near intracellular junctions in the DCT
while appearing more cytoplasmic in downstream segments.
More recent studies have documented WNK4 expression in
multiple chloride-transporting epithelia.2 The subcellular
distribution of WNK4 in these tissues is variable. WNK4
has been reported to localize near tight junctions, along
lateral membranes, and within the cytoplasm of various cells.
Based on these anatomical findings, the authors proposed
that the role of WNK4 in these tissues might be to regulate
transcellular and paracellular chloride permeability at multi-
ple sites.2
L-WNK1 and KS-WNK1
The full-length kinase-sufficient WNK1 transcript (herein
referred to as L-WNK1) is diffusely expressed in multiple
tissues.6 In contrast, a shorter isoform that contains a unique
exon at the extreme amino terminus and lacks a functional
kinase domain is expressed only in kidney. The expression of
this shorter, kidney-specific WNK1 transcript (KS-WNK1)
was confirmed by two independent groups.11,12 Using a
combination of in situ hybridization and reverse transcrip-
tase-polymerase chain reaction methods, both groups
documented the presence of L-WNK1 and KS-WNK1 in
kidney tissue, but noted that, while the L-WNK1 transcript is
expressed throughout the kidney at low levels, the KS-WNK1
transcript is expressed at much higher abundance, with an
anatomic distribution limited to the ASDN. More recently, in
situ hybridization studies by O’Reilly et al.12 (O’Reilly et al.
J Am Soc Nephrol 2005; 16: 171A) indicate that the expression
of KS-WNK1 is non-homogeneous; its abundance, at least at
the mRNA level, appears to be highest in DCT2, and tapers
down progressively across the more downstream segments of
the connecting tubule and cortical collecting duct. This
indicates that the two transcripts may have differential effects
on ASDN function, and suggests the possibility that activity
or expression of the two isoforms is regulated physiologically.
Upstream of exon 1, two WNK1 promoters initiate
transcription of the full-length isoform, whereas a down-
stream promoter that resides in intron 4 generates the
kidney-specific transcript.3 Naray-Fejes-Toth et al.13 reported
that KS-WNK1 transcription was enhanced by aldosterone in
a mineralocorticoid receptor-expressing cortical collecting
duct cell line; in contrast, the abundance of L-WNK1
transcript was not. The observations that KS-WNK1 is
expressed exclusively along the ASDN and is regulated by
aldosterone, together with earlier observations that WNK
mutations interfere with aldosterone action, suggest that KS-
WNK1 acts as an aldosterone-driven regulatory factor in the
distal nephron.
WNKS REGULATE SODIUM CHLORIDE AND POTASSIUM
TRANSPORT IN THE DISTAL NEPHRON
NCC
The thiazide sensitivity so commonly observed in FHHt
prompted investigators to study the effects of WNKs on NCC
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activity. Three groups reported that coexpression of WNK4
with NCC in Xenopus laevis oocytes inhibits thiazide-
sensitive sodium transport by more than 50% (Figure
1a).14–16 This effect is not related to a decrease in total
NCC protein abundance. Rather, immunofluorescence, sur-
face biotinylation, and semiquantitative confocal microscopic
studies suggest that the reduction in NCC activity is
secondary to a decrease in plasmalemmal co-transporter
density.
Two groups showed that WNK4 and NCC associate in a
protein complex involving the carboxyl terminus of
NCC.15,17 Wilson et al.15 tested the effect of a WNK4 mutant
believed to lack kinase activity, and found that it was
incapable of suppressing NCC-mediated Naþ transport. In
contrast, Yang et al.17 tested the same mutation, and found
no difference in its effect on NCC activity compared to wild-
type WNK4. The role of kinase activity in the effects of
WNK4 on NCC therefore remains unclear. Moreover,
evidence points to the presence of an NCC inhibitory region
at the WNK4 carboxyl terminus.17 In a series of deletion
experiments, Yang et al.17 found that coexpression of NCC
with a WNK4 construct that entirely lacks the kinase domain
fully suppresses NCC activity. The same group narrowed the
inhibitory region to a stretch of 50 residues at the extreme
carboxyl terminus of WNK4. This negative regulatory signal
domain is required for WNK4 to inhibit NCC activity,
although it is not the region of WNK4 that binds to NCC.
Rather, the NCC binding site appears to lie upstream of the
NRSD.17
Using the oocyte expression system, Yang et al.17 observed
that L-WNK1 does not affect NCC activity significantly when
both are expressed together. When L-WNK1 is coexpressed
with NCC and WNK4, however, L-WNK1 blocks the effects of
WNK4 (Figure 1a). Consistent with this finding, immuno-
fluorescence and surface biotinylation studies indicate that the
plasmalemmal expression of NCC is restored to baseline when
NCC, WNK4, and L-WNK1 are expressed together. Yang
et al.17 went on to show that the mechanism by which
L-WNK1 inhibits the effect of WNK4 on NCC requires three
components: (1) a physical association between the two
proteins in a complex involving the kinase domains, (2) intact
L-WNK1 catalytic activity, and (3) an L-WNK1 amino-acid
structure encoding the full-length protein.
The requirement for intact L-WNK1 catalytic activity
suggested that KS-WNK1 might possess different regulatory
effects on NCC compared to its full-length homolog. This
hypothesis was tested by coexpressing various combinations
of WNK4, L-WNK1, and KS-WNK1 with NCC in Xenopus
oocytes. In these studies, Subramanya et al.18 reported an
indirect effect of KS-WNK1 on NCC activity. This effect
occurs via L-WNK1, as KS-WNK1 inhibits L-WNK1-
mediated suppression of WNK4 in a dose-dependent manner
(Figure 1a). In vitro kinase assays demonstrated that the
kinase activity of L-WNK1 is quenched by KS-WNK1,
suggesting that the inhibitory effect of KS-WNK1 on NCC
may occur through the suppression of L-WNK1 catalytic
activity.18
These data suggest that WNK4, L-WNK1, and KS-WNK1
participate together in an inhibitory cascade that regulates
ion transport pathways. With regard to NCC, its activity is
inhibited by WNK4, which in turn is suppressed by L-WNK1
through a kinase-dependent mechanism. KS-WNK1 binds to
and blocks the kinase activity of L-WNK1, thereby quenching
the ability of L-WNK1 to block WNK4. This triple-inhibitory
effect is particularly relevant in the setting of high levels of
aldosterone, since the transcription of KS-WNK1 is induced
by mineralocorticoid. The high transcript abundance of
KS-WNK1 in DCT212 suggests that the protein abundance
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Figure 1 | (a) Summary of Xenopus laevis oocyte experiments
testing the effects of WNK4 and WNK1 gene products on
NCC-mediated Na–Cl co-transport. WNK4-(168–1222), a WNK4
construct that stably suppresses NCC,17 inhibits NCC activity by
greater than 50%. L-WNK1 has no direct effect on NCC, but
coexpression with WNK4 abrogates the inhibitory effect of WNK4
on NCC, restoring co-transporter activity to near baseline levels.
KS-WNK1 has no direct effect on NCC or WNK4; however, KS-WNK1
inhibits L-WNK1-mediated inhibition of WNK4 in a dose-dependent
manner (adapted from Subramanya et al.18) (b) Proposed effects of
WNK4 and WNK1 gene products on apical sodium and potassium
transport pathways in the late renal distal convoluted tubule (DCT2).
Under certain physiologic circumstances, aldosterone induces the
transcription of KS-WNK1, which helps convert Naþ reabsorption
from electroneutral (NCC) to electrogenic (ENaC). This augments
potassium secretion by increasing distal flow and luminal Naþ
concentration. KS-WNK1 also enhances potassium section by
increasing ROMK surface abundance, via its effect on L-WNK1.
See text for details.
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of KS-WNK1 is higher than that of L-WNK1 in this nephron
segment. Although studies have yet to definitively confirm
this at the level of protein expression, the high KS-WNK1:
L-WNK1 transcript ratio in DCT2 suggests that KS-WNK1
acts as a dominant-negative factor that suppresses electro-
neutral sodium transport.
ENaC
Wilson et al.1 suggested that the FHHt phenotype could not
be explained simply by an increase in ENaC activity.
Nevertheless, the renal localization of the WNK1 and
WNK4 gene products and presence of a glucocorticoid-
responsive element within the WNK1 gene suggested that the
epithelial sodium channel ENaC might be another target for
these kinases. Two groups have confirmed this hypothesis. Xu
et al.19,20 reported that L-WNK1 increases ENaC activity
through the PI3-kinase-dependent phosphorylation of
L-WNK1 at threonine-58, a residue N terminal to the
L-WNK1 kinase domain. Phosphorylation at this residue
subsequently results in the L-WNK1-mediated activation of
serum and glucocorticoid-regulated kinase SGK1. Activated
SGK1 phosphorylates the E3 ubiquitin–protein ligase Nedd4-
2, thereby inactivating it and allowing ENaC to remain at the
plasma membrane. Naray-Fejes-Toth et al.13 found that KS-
WNK1 activates ENaC-mediated Naþ transport as well, but
clearly this has to occur through an alternative mechanism, as
this WNK1 isoform lacks the exon containing threonine-58.
Nevertheless, it appears that the downstream mechanism
resulting in KS-WNK1-mediated activation of ENaC may
involve Nedd4-2 as well, since mutation of the Nedd4-2-
interacting carboxyl terminal P–Y domains of ENaC prevents
the regulatory event from taking place. To date, no published
studies have reported the effect of WNK4 on ENaC activity.
ROMK
FHHt-associated hyperkalemia is profound and seen early in
the disease, suggesting that WNK1 and WNK4 gene products
may regulate potassium flux. Kahle et al.2 tested this
hypothesis and found that WNK4 strongly downregulates
ROMK activity. The inhibitory effect of WNK4 on ROMK
was shown to be independent of kinase activity and results
from a decrease in channel surface expression; the effect is
dynamin-dependent, suggesting that the kinase affects
ROMK trafficking and facilitates the internalization of
ROMK through an endocytic mechanism.
Recent observations by two groups of investigators
working independently have documented differential effects
of the WNK1 isoforms on ROMK activity.21,22 L-WNK1
inhibits ROMK channel activity when the two are coex-
pressed in Xenopus oocytes or human embryonic kidney-293
cells. This mechanism appears to be dependent on L-WNK1
kinase activity, although direct phosphorylation of ROMK by
L-WNK1 has not been documented. KS-WNK1 has no
significant direct effect on the channel, but the kidney-
specific isoform blocks L-WNK1 activity in a dose-dependent
manner.21,22 In vivo dietary potassium experiments
performed in rats support these data, as high Kþ diets
(and consequently, high aldosterone levels) increase the
transcription and protein expression of KS-WNK1, which
would enhance the surface expression of ROMK and facilitate
potassium secretion. Consequently, these data suggest that
the antagonistic regulation of L-WNK1 by KS-WNK1 not
only bears relevance to NCC co-transport, but ROMK-
mediated potassium secretion as well.
Effects on paracellular chloride flux
Prior studies in human subjects with FHHt indicated that the
disease phenotype is dependent on excessive distal chloride
reabsorption.23,24 This finding, coupled with the colocaliza-
tion of WNK4 with tight junctions and prior observations
that a fraction of chloride reabsorption in the cortical
collecting duct occurs via paracellular routes, prompted two
groups of investigators to explore the effects of WNK4 on
paracellular chloride permeability. Both groups used a
polarized mammalian kidney epithelial cell line to show that
WNK4 overexpression selectively increases paracellular
chloride flux.25,26 This alteration in chloride permeability is
not associated with changes in tight junction structure.25 The
effect of WNK4 may be dependent on its catalytic activity, as
a putatively kinase-inactive WNK4 mutant had no effect on
paracellular chloride transport.25 WNK4 overexpression
enhances the phosphorylation of multiple claudins, proteins
that determine the characteristics of the paracellular ion
selectivity barrier.26 The kinase domain of WNK4 has also
been shown to directly phosphorylate claudin-4 in vitro,26
although these findings have not been reproduced by others.
To date, no published studies have described the effects of
L-WNK1 or KS-WNK1 on paracellular transport.
INTEGRATING THE MOLECULAR PHYSIOLOGY OF WNKS AND
DISTAL NEPHRON FUNCTION
The known effects of WNK4, L-WNK1, and KS-WNK1 on
sodium chloride and potassium transport in the DCT are
summarized in Figure 1b. WNK4 inhibits the activity of NCC
and ROMK and enhances paracellular chloride flux, but to
date, no effects on ENaC activity have been described.
L-WNK1 stimulates both ENaC- and NCC-mediated Naþ
transport; the former occurs through SGK1, and the latter
through the blockade of WNK4. However, since both of these
kinases independently suppress ROMK activity, they actually
synergize to inhibit potassium secretion. Finally, KS-WNK1
suppresses NCC transport via its dominant-negative effect on
L-WNK1, stimulates ROMK activity via the same antagonis-
tic mechanism, and enhances ENaC-mediated Naþ transport
through a different process.
These observations suggest that, under certain physiologic
circumstances, aldosterone simultaneously downregulates
electroneutral transport via NCC and enhances electrogenic
transport via ENaC and ROMK. Such a model makes sense
intuitively, as the inhibition of NCC activity by KS-WNK1
would increase flow to downstream nephron segments and
augment electrogenic sodium and potassium exchange.
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Increased flow would also activate maxi K channels, which
are now believed to play a central role in flow-stimulated Kþ
transport. Consequently, the inhibitory effect of KS-WNK1
on NCC activity would effectively maximize the dual
function of aldosterone as a mediator of both sodium
reabsorption and kaliuresis.
Clearly, we have only begun to understand the regulatory
network controlling sodium and potassium flux in the DCT.
In this mini review, we have attempted to integrate the
physiology derived from recent experimental data implicating
WNK1 and WNK4 gene products in the regulation of these
transport processes. The WNK field continues to grow
rapidly, and even during the short time that this manuscript
was written, new observations relevant to Naþ and Kþ
transport in the DCT came to light. In a recent series of
papers, the regulatory effects of WNK3 were reported.27,28
This paralog of WNK1 and WNK4 localizes to several tubular
segments of the nephron including the DCT, and strongly
upregulates NCC activity in Xenopus oocytes, possibly
through increasing the degree of co-transporter phosphor-
ylation. WNK3 has no detectable effect on paracellular
chloride permeability or ENaC activity, but downregulates
ROMK activity by greater than fivefold.27 The effects on NCC
activity are essentially reversed when the kinase-active form is
replaced in otherwise identical experiments with a kinase-
dead mutant. These robust and intriguing results suggest that
WNK3 might play a crucial role in the mechanisms that
coordinate renal sodium and potassium excretion. It will
therefore be of great interest to investigate how this new
addition to the WNK signaling network impacts the action of
the other family members that it is coexpressed with in the
ASDN.
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